Key players, such as Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others, are active in the Kaposi’s Sarcoma therapeutics domain. The emerging therapies which are under development are expected to provide efficient therapeutic approaches with a novel mechanism of action for the treatment of patients affected with Kaposi’s Sarcoma
DelveInsight’s “Kaposi’s Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Kaposi’s Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Kaposi’s Sarcoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Kaposi’s Sarcoma: An Overview
Kaposi’s Sarcoma (KS) is a multi-centric vascular tumor originating in the endothelial cells that line blood vessels and lymphatic vessels. KS is caused when tiny blood vessels develop below the surface of the skin, in the mouth, nose, eyes, or other parts of the body, such as the lymph nodes or lungs. Individuals with weak immune systems, especially HIV patients, have a high risk of Kaposi’s Sarcoma. The lesions of Kaposi’s Sarcoma typically appear as painless purplish spots on the feet, legs, face, genital area, mouth, or lymph nodes. In severe Kaposi’s Sarcoma, lesions may develop in the lungs and digestive tract.
Kaposi’s Sarcoma is caused by infection with a virus called Kaposi sarcoma-associated herpesvirus (KSHV), which is also known as herpesvirus 8 (HHV8). KSHV is in the same family as Epstein-Barr virus (EBV), the virus that causes infectious mononucleosis (mono) and is linked to several types of cancer.
There are four main forms of Kaposi’s Sarcoma: Epidemic or AIDS-associated KS, Classic KS, Endemic KS, and Immunosuppressive Kaposi’s Sarcoma. All forms of Kaposi’s Sarcoma (KS) are more common in men than in women.
Kaposi’s Sarcoma Market Key Facts
As per Globocan (2020), the prevalence rate of Kaposi Sarcoma is 1.11 per 100,000 in the United States, and its prevalence in the United Kingdom and Japan was found to be around 0.81/100,000 and 0.13/100,000, respectively.
As per the study titled “Risk of Kaposi’s Sarcoma after solid organ transplantation in the United States” conducted by Cahoon et al. (2018), KS incidence was 87% higher in men than women, over twofold greater in non-whites than whites, and two-fold higher in non‐US citizens than US citizens. KS incidence increased with age at transplant and decreased sharply with time since transplant, so the highest incidence occurred within 1 year of transplant.
KS was a rare disease before the AIDS epidemic in the early 1980s when the reported incidence of classic KS ranged from 0.01 per 100,000 person-years for the UK and 0.2 per 100,000 person-years for the USA. The incidence of KS is currently reported to be ~200.
Kaposi’s Sarcoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Kaposi’s Sarcoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Kaposi’s Sarcoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Kaposi’s Sarcoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Kaposi’s Sarcoma Epidemiology, Segmented as –
Prevalent cases of Kaposi’s Sarcoma in 7MM [2019–2032]
Total Diagnosed cases of Kaposi’s Sarcoma in the 7MM [2019–2032]
Age-specific Cases of Kaposi’s Sarcoma in 7MM [2019–2032]
Total Treated Cases of Kaposi’s Sarcoma in 7MM [2019–2032]
Gender-specific Cases of Kaposi’s Sarcoma in 7MM [2019–2032]
Kaposi’s Sarcoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Kaposi’s Sarcoma market or expected to be launched during the study period. The analysis covers the Kaposi’s Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Kaposi’s Sarcoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Kaposi’s Sarcoma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/kaposis-sarcoma-market
Kaposi’s Sarcoma Therapeutics Analysis
The main forms of treatment for Kaposi’s Sarcoma are Antiretroviral Therapy, Surgery, Photodynamic Therapy, Radiation Therapy, and therapies using medications such as Chemotherapy, Topical medications, Targeted Therapy, and Immunotherapy.
At present, very few companies have initiated clinical trials that investigate new treatment options. Key players such as Vasgene Therapeutics (sEphB4-HAS), Bristol-Myers Squibb (Nivolumab and Ipilimumab), and several others are investigating their candidates for the management of Kaposi’s Sarcoma in the 7MM. Currently, Vasgene Therapeutics is leading the therapeutics market with its Kaposi’s sarcoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Kaposi’s Sarcoma Therapeutics Market Include:
Vasgene Therapeutics
Bristol Myers Squibb
SkinDermic
Aphios
TTY Biopharm
NeoImmuneTech
Cello Therapeutics
And Many Others
Kaposi’s sarcoma Emerging and Marketed Drugs Covered in the Report Include:
sEphB4-HAS: Vasgene Therapeutics
Nivolumab and Ipilimumab: Bristol-Myers Squibb
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Kaposi’s Sarcoma Competitive Intelligence Analysis
4. Kaposi’s Sarcoma Market Overview at a Glance
5. Kaposi’s Sarcoma Disease Background and Overview
6. Kaposi’s Sarcoma Patient Journey
7. Kaposi’s Sarcoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Kaposi’s Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Kaposi’s Sarcoma Unmet Needs
10. Key Endpoints of Kaposi’s Sarcoma Treatment
11. Kaposi’s Sarcoma Marketed Products
12. Kaposi’s Sarcoma Emerging Drugs and Latest Therapeutic Advances
13. Kaposi’s Sarcoma Seven Major Market Analysis
14. Attribute Analysis
15. Kaposi’s Sarcoma Market Outlook (In US, EU5, and Japan)
16. Kaposi’s Sarcoma Access and Reimbursement Overview
17. KOL Views on the Kaposi’s Sarcoma Market
18. Kaposi’s Sarcoma Market Drivers
19. Kaposi’s Sarcoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
